March 23 (Reuters) - Oryzon Genomics SA ORY.MC:
ANNOUNCES U.S. PATENT GRANT COVERING IADADEMSTAT COMBINATIONS WITH VENETOCLAX
KEY COMBINATION FOR THE TREATMENT OF FIRST-LINE ACUTE MYELOID LEUKEMIA (AML)
PATENT EXPECTED TO EXPIRE IN JAN 2039
Source text: https://tinyurl.com/yb5rkhfj